Bailard’s Oruka Therapeutics ORKA Stock Holding History

Bailard’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,917	Closed	-$87K	–	774
2022 Q2	$87K	Buy	+2,917	New	+$82.5K	﹤0.01%	664

Other funds holding ORKA

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SG3 Management Dorado, Puerto Rico $6.45K AUM 61.81% 1-Year Est. Return

Bailard's ORKA Position: Q3 2022 in Review

Bailard sold out of Oruka Therapeutics (ORKA) in Q3 2022, closing a stake of 2,917 shares — an estimated $87K sold.

Bailard first reported a position in ORKA in Q2 2022 and held it in 1 quarter. The position peaked at $87K in Q2 2022. 25 funds tracked by Wall St. Rank hold ORKA as of Q3 2022.

Bailard reported no remaining Oruka Therapeutics position as of Q3 2022 after selling out during the quarter.
Bailard sold 2,917 Oruka Therapeutics shares in Q3 2022, an estimated $87K.
Bailard first reported a position in Oruka Therapeutics in Q2 2022 and held it in 1 quarter.
Bailard's Oruka Therapeutics position peaked at $87K in Q2 2022.
25 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.